Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
about
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchDenosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoringUK clinical guideline for the prevention and treatment of osteoporosisBisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Osteoporosis: "A risk factor for periodontitis"Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.Bisphosphonate drug holidays: Can we recommend currently?Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.Central dislocation of the hip secondary to insufficiency fractureDifferences between the bisphosphonates for the prevention and treatment of osteoporosis.Effect of stopping risedronate after long-term treatment on bone turnover.Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.A reappraisal of generic bisphosphonates in osteoporosis.Femoral stress fractures associated with long-term bisphosphonate treatment.Alendronate sodium in the management of osteoporosis.The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 yearsOsteoporosis: how should it be treated?Drug insight: Existing and emerging therapies for osteoporosis.Osteoporosis and periodontal disease.Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosisAdherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review.Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.Fracture risk associated with chronic use of bisphosphonates: evidence today.Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Incidence and demography of femur fractures with and without atypical features.Bone turnover markers: use in osteoporosis.Decreased bone mineral density and periodontal management.Association between fat mass, lean mass, and bone loss: the Dubbo Osteoporosis Epidemiology Study.Treatment of osteoporosis after alendronate or risedronate.
P2860
Q26782621-C9F8B656-2EB1-4BBB-BC74-7015199BF5C4Q30978614-E5A31F87-5F2D-4043-9F86-A0F76FE849C5Q33268786-27DB4060-BF8F-42CB-B573-7C7FB8209561Q33570209-BDA64686-3AF3-40AE-A5D8-566034C51466Q33581078-40AFE727-7220-4AF7-BDFB-24B5137ABFEDQ33715141-2D7A48C8-ADA4-4CAD-98D9-15DE6753190BQ33759893-5D4129AC-7849-472C-895C-3BDC777BD5B6Q33898842-7C1D6833-711E-4DF2-99D7-EF3AF652AEA8Q33984172-78D5C4B2-E2AB-41B3-8583-472D9F5EBD5EQ34018048-1A7D641D-0DF4-4704-9180-7AEC06CE7060Q34149279-99144EEC-755E-4849-A0B8-3C660556DDE7Q34283690-F814FBF8-9447-457A-8A68-C8E18339A4DDQ34329746-A48501A8-B69C-4959-AF23-CAF9A7C6C98EQ34440107-64ADCDDB-2B52-4CEF-98C6-9B8562878DF2Q34522113-F4ADBB43-3859-4332-9460-1A30053FF3C3Q35128848-FC58B568-42CD-4ACD-A73C-495654503575Q35166767-C0EED609-912C-4745-9C82-39FB3A260F88Q35498057-38155AF2-B24C-4C94-88B4-839B7EFA6193Q35536507-84BD2208-59A7-4525-BE71-26D1EC869131Q35590586-EC4CD46D-D453-480D-B4FB-8B2D5010F49DQ35644168-1AB8A7C5-E96C-4168-8C70-97CB0B32043AQ35723090-DB21D7E2-FE03-4137-9485-0333B996A31DQ35919111-C2A85411-B8C1-43FA-853B-DB06E2DF2C6EQ36190027-C90B5C32-4C21-4939-AE41-74F5A97E241BQ36309349-77D061B1-1EB1-4061-B3F7-F19EF9C1A3ECQ36583646-4FAAF279-41CE-45CE-ABE5-0D0CF230975CQ36672697-8C21415D-406D-4BCA-82AB-1F1213B34C06Q36809161-A76C192F-29B6-4505-8EA0-1D8268827753Q36922156-A6F69F1F-C30F-498C-AF08-B76EADA9C41EQ37197298-E84C35F8-2B1E-4CF4-8CAC-0A18A94CCF67Q37315766-314F2859-6320-478A-A7F6-49FED966C86FQ37360702-047EAE93-2705-4E24-9F08-75009CB9F02EQ37401870-3DD737E8-3770-422C-B5D6-22E71570AB52Q37814414-82F6B6F9-1458-49A2-A070-C08CA9D318CDQ37862933-B9176DD3-F111-4666-AD1F-0B7C2A802165Q37978565-E1610973-9882-485D-B603-CDE0CF530530Q38016073-605B5466-0C9E-45E6-8598-822047E32F87Q38067478-207D1EEB-4FE3-4CCA-8E6D-B96060562376Q38429885-AA1DA371-906C-415E-89EF-CC3FFCEE18D4Q38599682-539E8CD4-953D-4A79-B8D7-0A4F9F14BC11
P2860
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Randomized trial of effect of ...... ion Trial long-term extension.
@en
Randomized trial of effect of ...... ion Trial long-term extension.
@nl
type
label
Randomized trial of effect of ...... ion Trial long-term extension.
@en
Randomized trial of effect of ...... ion Trial long-term extension.
@nl
prefLabel
Randomized trial of effect of ...... ion Trial long-term extension.
@en
Randomized trial of effect of ...... ion Trial long-term extension.
@nl
P2093
P2860
P356
P1476
Randomized trial of effect of ...... ion Trial long-term extension.
@en
P2093
Adrianne Feldstein
Ann Schwartz
Antonio Lombardi
Arthur C Santora
Dennis M Black
Douglas C Bauer
Elizabeth L Barrett-Connor
Fracture Intervention Trial Long-Term Extension Research Group
James C Torner
Kristine E Ensrud
P2860
P304
P356
10.1359/JBMR.040326
P577
2004-03-29T00:00:00Z